<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00683696</url>
  </required_header>
  <id_info>
    <org_study_id>EchoCRT</org_study_id>
    <nct_id>NCT00683696</nct_id>
  </id_info>
  <brief_title>Echocardiography Guided Cardiac Resynchronization Therapy (EchoCRT)</brief_title>
  <acronym>EchoCRT</acronym>
  <official_title>Echocardiography Guided Cardiac Resynchronization Therapy (EchoCRT)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Biotronik, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Zurich</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Biotronik, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The EchoCRT trial evaluates the effects of Cardiac Resynchronization Therapy (CRT) on
      mortality and morbidity of subjects with heart failure due to left ventricular systolic
      dysfunction, already receiving optimized HF medication, with a narrow QRS width (&lt; 130 ms)
      and echocardiographic evidence of ventricular dyssynchrony.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <start_date>August 2008</start_date>
  <completion_date type="Actual">March 2013</completion_date>
  <primary_completion_date type="Actual">March 2013</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Composite Primary Endpoint: Number of Subjects With First Hospitalization for Worsening Heart Failure or Death</measure>
    <time_frame>From date of randomization until date of death from any cause or date of first hospitalization for worsening heart failure, whichever came first, assessed up to date of study exit, with a mean treatment duration of 1.6 years</time_frame>
    <description>The primary efficacy endpoint will evaluate the effect of CRT=ON versus CRT=OFF in time to event of a combined endpoint of all-cause mortality or first hospitalization for worsening heart failure.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Subjects That Underwent Implant Attempt Without System- or Implant-Related Complications (Complication-Free)</measure>
    <time_frame>6 months</time_frame>
    <description>The primary safety endpoint will evaluate the complication-free rate of the Lumax HF-T CRT-D devices in the narrow QRS subject population.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rate of Hospitalizations for Worsening Heart Failure (Hospitalizations Per Subject-year)</measure>
    <time_frame>Study duration from randomization to study exit</time_frame>
    <description>Evaluate the effects of CRT=ON compared to CRT=OFF on the rate of hospitalization for worsening heart failure (WHF).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>New York Heart Association (NYHA) Classification Change</measure>
    <time_frame>6 months</time_frame>
    <description>Evaluate the effects of CRT=ON compared to CRT=OFF in relation to the change in NYHA classification.
NYHA classes:
Class I - Subjects with cardiac disease, but without resulting limitation of physical activity. Ordinary physical activity does not cause undue fatigue, palpitation,dyspnea, or anginal pain.
Class II - Subjects with cardiac disease resulting in slight limitation of physical activity. They are comfortable at rest. Ordinary physical activity results in fatigue, palpitation, dyspnea, or anginal pain.
Class III - Subjects with cardiac disease resulting in marked limitation of physical activity. They are comfortable at rest. Less than ordinary activity causes fatigue, palpitation, dyspnea, or anginal pain.
Class IV - Subjects with cardiac disease resulting in inability to carry on any physical activity without discomfort. Symptoms of cardiac insufficiency or of anginal syndrome may be present even at rest. If any physical activity is undertaken, discomfort is increased.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Quality of Life (QOL) Scores From Baseline to 6-Month Follow-up</measure>
    <time_frame>Changes between baseline and 6 months</time_frame>
    <description>Quality of Life was evaluated using the Minnesota Living with Heart Failure (MLHF) Quality of Life (QOL) Questionnaire.The questionnaire consists of 21 questions to measure the subjects' perception of how their HF and its treatment affected their ability to live as they wanted during the last month. The questions describe different ways in which some people are affected (i.e. physical, socioeconomic, and psychological impairments). If a question does not apply to a subject or is not related to their HF, then they can answer with a 0. If it does apply to them, then they can rate (from 1 to 5) how much it has affected them. From the 21 questions, the lowest possible total score is 0, and the highest possible total score is 105. A lower score is desirable. Therefore, a negative change in QOL score from baseline to 6 months represents an improvement in quality of life, while a positive change in QOL score from baseline to 6 months represents a worsening in quality of life.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Composite Score of Death, Hospitalization for Worsening Heart Failure and Change in Quality of Life (QOL)</measure>
    <time_frame>Composite of death, worsening heart failure hospitalization (up to 24 months), and change in QOL (at 6 months)</time_frame>
    <description>Evaluate the effects of CRT=ON compared to CRT=OFF in relation to a composite endpoint of all-cause mortality, hospitalization for worsening heart failure and change in the MLHF Quality of Life Questionnaire.
This composite endpoint used a weighted scoring scale based on the African-American Heart Failure Trial (A-HeFT) study Endpoint Score. (Taylor, AL, Ziesche, S, Yancy, C, et al. Combination of Isosorbide Dinitrate and Hydralazine in Blacks with Heart Failure. N Engl J Med 2004; 351:2049-57.)
Composite Endpoint Scoring:
Vital Status:
Death (-3),
Survival to end of trial (0),
Hospitalization:
1st hospitalization for HF (-1),
No hospitalization (0),
QOL score:*
Improvement by ≥ 10 units (+2),
Improvement by 5-9 units (+1),
Change by &lt; 5 units (0),
Worsening by 5-9 units (-1),
Worsening by ≥ 10 (-2).
Possible total score -6 to +2.
*QOL score details are provided in Secondary Outcome Measure 5.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With All-cause Mortality</measure>
    <time_frame>From date of randomization up to date of study exit, with a mean treatment duration of 1.6 years</time_frame>
    <description>Evaluate the all-cause mortality rate between the CRT=ON compared to CRT=OFF group.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">1680</enrollment>
  <condition>Heart Failure</condition>
  <condition>Ventricular Dyssynchrony</condition>
  <arm_group>
    <arm_group_label>CRT=ON</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cardiac Resynchronization Therapy activated.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CRT=OFF</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Cardiac Resynchronization Therapy deactivated.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Implantable Cardioverter Defibrillator with Cardiac Resynchronization Therapy (BIOTRONIK Lumax HF-T CRT-D)</intervention_name>
    <description>All patients will receive a commercially available BIOTRONIK Lumax HF-T CRT-D system with ICD back-up enabled. Patients will be randomized to CRT=ON or CRT=OFF.</description>
    <arm_group_label>CRT=ON</arm_group_label>
    <arm_group_label>CRT=OFF</arm_group_label>
    <other_name>Lumax HF-T CRT-D system</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Men and women 18 years of age or older.

          -  Understand the nature of the procedure.

          -  Give written informed consent.

          -  Willing and able to complete all testing required by the clinical protocol.

          -  Indication for an implantable cardioverter defibrillator (ICD).

          -  NYHA class III-IV within the last three months prior to enrollment and at baseline (at
             baseline only: also Stage C according to ACC/AHA guidelines).

          -  Stable optimal pharmacologic therapy for HF.

          -  An ejection fraction ≤ 35% within one year prior to enrollment and confirmed on the
             baseline echocardiogram.

          -  Increased left ventricular dimension, defined as LVEDD ≥ 55 mm.

          -  Resting QRS duration &lt; 130 ms evidenced by a historical 12-lead ECG prior to
             enrollment and at baseline.

          -  Ventricular dyssynchrony assessed by echocardiography locally and confirmed by the
             echo core lab. One of the two following criteria has to be present to include the
             subject in the study:

               -  Intra-left ventricular dyssynchrony measured by color Tissue Doppler Imaging
                  (TDI) with an opposing wall delay of ≥ 80 ms in the 4-chamber or apical long-axis
                  view.

               -  Speckle-tracking radial strain septal-posterior wall delay ≥ 130 ms.

        Exclusion Criteria:

          -  Implanted pacemaker or defibrillator with &gt;10% ventricular pacing, as demonstrated by
             device statistics averaged over at least the last three months prior to enrollment.

          -  Women who are pregnant, lactating, or planning to become pregnant during the course of
             the trial.

          -  Bradycardia pacing indication.

          -  Surgically correctable primary valvular heart disease, i.e. aortic stenosis, torn
             cordae, or flail segment.

          -  Coronary artery bypass graft surgery or percutaneous coronary intervention (balloon
             and/or stent angioplasty) within the past 3 months prior to enrollment.

          -  Enzyme-positive myocardial infarction within the past 3 months prior to enrollment.

          -  Angiographic evidence of coronary disease, candidates for coronary revascularization
             likely to undergo coronary artery bypass graft surgery or percutaneous coronary
             intervention in the next 3 months.

          -  Irreversible brain damage from preexisting cerebral disease.

          -  Reversible non-ischemic cardiomyopathy such as acute viral myocarditis.

          -  Permanent second or third degree heart block.

          -  Chagas disease.

          -  Persistent or paroxysmal atrial fibrillation within one month prior to enrollment.

          -  Expected to receive heart transplantation within six months.

          -  Current inotropic therapy.

          -  Acutely decompensated heart failure.

          -  Contrast dye allergy and unable or unwilling to undergo pretreatment with steroids
             and/or diphenhydramine.

          -  Life expectancy of less than six months.

          -  Presence of any disease, other than the subject's cardiac disease associated with a
             reduced likelihood of survival for the duration of the trial, (e.g. cancer).

          -  Significant renal insufficiency defined as a serum creatinine &gt; 2.5 mg/dL (&gt; 221
             µmol/L) within the last four weeks prior to enrollment..

          -  Liver failure, defined as three times the upper limit of normal for aminotransferases.

          -  Participation in any other clinical trial.

          -  Unable to return for follow-up visits due to distance from the clinic.

          -  Do not anticipate being a resident of the area for the scheduled duration of the
             trial.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Frank Ruschitzka, MD</last_name>
    <role>Study Chair</role>
    <affiliation>University of Zurich, Switzerland</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Johannes Holzmeister, MD</last_name>
    <role>Study Chair</role>
    <affiliation>University of Zurich, Switzerland</affiliation>
  </overall_official>
  <overall_official>
    <last_name>William Abraham, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Principal Investigator (USA) at The Ohio State University, OH, USA</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jagmeet Singh, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Principal Investigator (USA) at Massachusetts General Hospital, MA, USA</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>John Muir Medical Center</name>
      <address>
        <city>Concord</city>
        <state>California</state>
        <zip>94520</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cedars-Sinai Medical Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90048</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Desert Cardiology</name>
      <address>
        <city>Rancho Mirage</city>
        <state>California</state>
        <zip>92270</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California San Francisco</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cardiology Associates Medical Group</name>
      <address>
        <city>Ventura</city>
        <state>California</state>
        <zip>93003</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hartford Hospital</name>
      <address>
        <city>Hartford</city>
        <state>Connecticut</state>
        <zip>06102</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Osceola Regional Medical Center</name>
      <address>
        <city>Kissimmee</city>
        <state>Florida</state>
        <zip>34741</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Miami</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tampa General Hospital</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33606</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tampa General Medical Center</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Piedmont Hospital</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30309</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Emory University</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saint Joseph's Hospital</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northwestern University</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Francis Medical Group</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46237</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Community Heart and Vascular</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46250</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Central Baptist Hospital</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40503</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114-2696</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boston Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02118</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beth Israel Deaconess Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boston Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Massachusetts</name>
      <address>
        <city>Worcester</city>
        <state>Massachusetts</state>
        <zip>01655</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bay Regional Medical Center</name>
      <address>
        <city>Bay City</city>
        <state>Michigan</state>
        <zip>48708</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Thoracic &amp; Cardiovascular Healthcare Foundation</name>
      <address>
        <city>Lansing</city>
        <state>Michigan</state>
        <zip>48910</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Michigan Heart, P.C./ St. Joseph Mercy Hospital</name>
      <address>
        <city>Ypsilanti</city>
        <state>Michigan</state>
        <zip>48197</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>United Heart and Vascular Center</name>
      <address>
        <city>Saint Paul</city>
        <state>Minnesota</state>
        <zip>55102</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>North Mississippi Medical Center</name>
      <address>
        <city>Tupelo</city>
        <state>Mississippi</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kansas City Heart Foundation</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64132</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Medical Center</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64132</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Medical Center</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington University</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63102</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Deborah Heart and Lung Center</name>
      <address>
        <city>Browns Mills</city>
        <state>New Jersey</state>
        <zip>08015</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Montefiore Medical Center</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10467</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Lukes-Roosevelt Hospital Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10025</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Rochester</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14642</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stony Brook University Medical Center</name>
      <address>
        <city>Stony Brook</city>
        <state>New York</state>
        <zip>11794</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanger Heart &amp; Vascular Institute</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duke University</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lindner Clinical Trial Center</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45219</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Cincinnati</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45219</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44145</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Ohio State University Richard M. Ross Heart Hospital</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Promedica Northwest Ohio Cardiology Consultants</name>
      <address>
        <city>Toledo</city>
        <state>Ohio</state>
        <zip>43615</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oregon Health Sciences University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lehigh Valley Heart Specialists</name>
      <address>
        <city>Allentown</city>
        <state>Pennsylvania</state>
        <zip>18103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Drexel Cardiology</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jefferson Heart Institute, Thomas Jefferson University Hospital</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pittsburgh Medical Center</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>South Carolina Heart Center</name>
      <address>
        <city>Columbia</city>
        <state>South Carolina</state>
        <zip>29204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Stern Cardiovascular Center</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38138</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cardiology Center of Amarillo</name>
      <address>
        <city>Amarillo</city>
        <state>Texas</state>
        <zip>79106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Cardiac Arrhythmia</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cardiology Associates of Corpus Christi</name>
      <address>
        <city>Corpus Christi</city>
        <state>Texas</state>
        <zip>78404</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Virginia</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22908</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>INOVA Fairfax Hospital</name>
      <address>
        <city>Falls Church</city>
        <state>Virginia</state>
        <zip>22042</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bon Secours Heart &amp; Vascular Institute</name>
      <address>
        <city>Mechanicsville</city>
        <state>Virginia</state>
        <zip>23116</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Virginia Cardiovascular Specialists</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23225</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bon Secours Heart &amp; Vascular Institute</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Virginia Cardiovascular Specialists</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cardiovascular Associates Ltd</name>
      <address>
        <city>Virginia Beach</city>
        <state>Virginia</state>
        <zip>23454</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kootenai Heart Clinics</name>
      <address>
        <city>Spokane</city>
        <state>Washington</state>
        <zip>99204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Aurora Cardiovascular Services</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Flinders Medical Center Adelaide</name>
      <address>
        <city>Adelaide</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Princess Alexandra Hospital</name>
      <address>
        <city>Brisbane</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Vincent's Hospital</name>
      <address>
        <city>Melbourne</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sir Charles Gairdner Hospital</name>
      <address>
        <city>Nedland</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Perth Hospital</name>
      <address>
        <city>Perth</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>LKH Universitatsklinikum Graz</name>
      <address>
        <city>Graz</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>OLV Hospital (OLV Ziekenhuis) Aalst</name>
      <address>
        <city>Aalst</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitair Ziekenhuis Brussel</name>
      <address>
        <city>Brussels</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UHN Toronto General Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Edmonton Cardiology</name>
      <address>
        <city>Edmonton</city>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Olomouc University Hospital</name>
      <address>
        <city>Olomouc</city>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IKEM - Institute for Clinical and Experimental Medicine</name>
      <address>
        <city>Prague</city>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Na Homolce Hospital</name>
      <address>
        <city>Prague</city>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Aalborg Sygehus</name>
      <address>
        <city>Aalborg</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Skejby Sygehus Aarhus</name>
      <address>
        <city>Aarhus</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rigshospitalet</name>
      <address>
        <city>Copenhagen</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gentofte Hospital</name>
      <address>
        <city>Hellerup</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nouvelles Cliniques Nantes</name>
      <address>
        <city>Nantes</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Pontchaillou de Rennes</name>
      <address>
        <city>Rennes</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Charles Nicolle</name>
      <address>
        <city>Rouen</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Herz- und Diabeteszentrum NRW</name>
      <address>
        <city>Bad Oeynhausen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Charite Campus Virchow Klinikum</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Judisches Krankenhaus Berlin</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Evangelisch-Freikirchliches Krankenhaus und Herzzentrum Brandenburg in Bernau</name>
      <address>
        <city>Bernau</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alfried Krupp Krankenhaus</name>
      <address>
        <city>Essen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Elisabeth-Krankenhaus Essen</name>
      <address>
        <city>Essen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Westdeutsches Herzzentrum Essen</name>
      <address>
        <city>Essen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Asklepios Klinik St. Georg Hamburg</name>
      <address>
        <city>Hamburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitares Herzzentrum Hamburg GmbH</name>
      <address>
        <city>Hamburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitatsklinikum Jena</name>
      <address>
        <city>Jena</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Herzzentrum Leipzig GmbH</name>
      <address>
        <city>Leipzig</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Marien Hospital Lunen</name>
      <address>
        <city>Lunen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Lüdenscheid</name>
      <address>
        <city>Lüdenscheid</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital of Magdeburg</name>
      <address>
        <city>Magdeburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Barzilai Medical Center</name>
      <address>
        <city>Ashkelon</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Soroka Medical Center</name>
      <address>
        <city>Beer Sheva</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hadassah Medical Organization</name>
      <address>
        <city>Jerusalem</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sourasky Medical Center</name>
      <address>
        <city>Tel Aviv</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sheba Medical Center</name>
      <address>
        <city>Tel Hashomer</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>A.O.U. Consorziale Policlinico di Bari</name>
      <address>
        <city>Bari</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>A.O. Spedali Civili di Brescia</name>
      <address>
        <city>Brescia</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>P.O. Santa Maria di Loreto Nuovo</name>
      <address>
        <city>Naples</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>A.O.U. Maggiore della Carita</name>
      <address>
        <city>Novara</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>VU MC Amsterdam</name>
      <address>
        <city>Amsterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Leiden University Medical Center</name>
      <address>
        <city>Leiden</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instytut Kardiologii</name>
      <address>
        <city>Warsaw</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>4 Wojskowy Szpital Kliniczny</name>
      <address>
        <city>Wroclaw</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Santa Maria de Lisboa</name>
      <address>
        <city>Lisbon</city>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Santa Marta</name>
      <address>
        <city>Lisbon</city>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Alicante General Hospital</name>
      <address>
        <city>Alicante</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clinic of Barcelona</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopitaux Universitaires de Geneve</name>
      <address>
        <city>Geneve</city>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Vaudois Lausanne</name>
      <address>
        <city>Lausanne</city>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Triemli Hospital (Stadtspital Triemli)</name>
      <address>
        <city>Zurich</city>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Zurich Hospital</name>
      <address>
        <city>Zurich</city>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospitals of Coventry and Warwickshire</name>
      <address>
        <city>Coventry</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Glenfield Hospital</name>
      <address>
        <city>Leicester</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. George's Hospital</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Thomas' Hospital</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Russells Hall Hospital</name>
      <address>
        <city>West Midlands</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Austria</country>
    <country>Belgium</country>
    <country>Canada</country>
    <country>Czechia</country>
    <country>Denmark</country>
    <country>France</country>
    <country>Germany</country>
    <country>Israel</country>
    <country>Italy</country>
    <country>Netherlands</country>
    <country>Poland</country>
    <country>Portugal</country>
    <country>Spain</country>
    <country>Switzerland</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Czech Republic</country>
  </removed_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 30, 2007</study_first_submitted>
  <study_first_submitted_qc>May 21, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 23, 2008</study_first_posted>
  <results_first_submitted>March 12, 2014</results_first_submitted>
  <results_first_submitted_qc>March 12, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">April 17, 2014</results_first_posted>
  <last_update_submitted>January 12, 2018</last_update_submitted>
  <last_update_submitted_qc>January 12, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 17, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Cardiac Resynchronization Therapy</keyword>
  <keyword>Heart Failure</keyword>
  <keyword>Ventricular Dyssynchrony</keyword>
  <keyword>Mechanical Dyssynchrony</keyword>
  <keyword>Intraventricular Dyssynchrony</keyword>
  <keyword>Echocardiography</keyword>
  <keyword>Normal QRS</keyword>
  <keyword>Heart Disease</keyword>
  <keyword>EchoCRT</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>After enrollment, baseline eligibility criteria were assessed (e.g. ventricular dyssynchrony, NYHA, QRS width, etc.) to qualify for implant. 1680 subjects were enrolled. 825 subjects did not qualify for implant and were exited from the study. 855 subjects qualified for implant. 821 subjects were successfully implanted. 809 subjects were randomized.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>CRT=ON</title>
          <description>Cardiac Resynchronization Therapy activated.
Subject implanted with BIOTRONIK Lumax HF-T CRT-D system with ICD back-up enabled and randomized to CRT=ON.</description>
        </group>
        <group group_id="P2">
          <title>CRT=OFF</title>
          <description>Cardiac Resynchronization Therapy deactivated.
Subject implanted with BIOTRONIK Lumax HF-T CRT-D system with ICD back-up enabled and randomized to CRT=OFF.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="404"/>
                <participants group_id="P2" count="405"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="404"/>
                <participants group_id="P2" count="405"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawn due to study closure</title>
              <participants_list>
                <participants group_id="P1" count="337"/>
                <participants group_id="P2" count="338"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawn prior to study closure</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="28"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Vital status follow-up only</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="46"/>
                <participants group_id="P2" count="30"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Baseline characterisics were analzed for the randomized population.</population>
      <group_list>
        <group group_id="B1">
          <title>CRT=ON</title>
          <description>Cardiac Resynchronization Therapy activated.</description>
        </group>
        <group group_id="B2">
          <title>CRT=OFF</title>
          <description>Cardiac Resynchronization Therapy deactivated.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="404"/>
            <count group_id="B2" value="405"/>
            <count group_id="B3" value="809"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="57.6" spread="12.9"/>
                    <measurement group_id="B2" value="58.3" spread="12.6"/>
                    <measurement group_id="B3" value="58.0" spread="12.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="110"/>
                    <measurement group_id="B2" value="114"/>
                    <measurement group_id="B3" value="224"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="294"/>
                    <measurement group_id="B2" value="291"/>
                    <measurement group_id="B3" value="585"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Portugal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="196"/>
                    <measurement group_id="B2" value="198"/>
                    <measurement group_id="B3" value="394"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Spain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Austria</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Israel</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>United Kingdom</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Switzerland</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Italy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>France</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Czech Republic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Canada</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Poland</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Belgium</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Australia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Denmark</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                    <measurement group_id="B2" value="23"/>
                    <measurement group_id="B3" value="47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Germany</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="41"/>
                    <measurement group_id="B2" value="41"/>
                    <measurement group_id="B3" value="82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Netherlands</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Composite Primary Endpoint: Number of Subjects With First Hospitalization for Worsening Heart Failure or Death</title>
        <description>The primary efficacy endpoint will evaluate the effect of CRT=ON versus CRT=OFF in time to event of a combined endpoint of all-cause mortality or first hospitalization for worsening heart failure.</description>
        <time_frame>From date of randomization until date of death from any cause or date of first hospitalization for worsening heart failure, whichever came first, assessed up to date of study exit, with a mean treatment duration of 1.6 years</time_frame>
        <population>This analysis was carried out according to the intention-to-treat principle. Follow-up was censored at study closure, date of death, LVAD, heart transplant, withdrawal from the study, or loss to follow-up, whichever came first. 4 deaths in CRT OFF group and 1 death in CRT ON group were after LVAD/transplant and are not included in this analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>CRT=ON</title>
            <description>Cardiac Resynchronization Therapy activated.</description>
          </group>
          <group group_id="O2">
            <title>CRT=OFF</title>
            <description>Cardiac Resynchronization Therapy deactivated.</description>
          </group>
        </group_list>
        <measure>
          <title>Composite Primary Endpoint: Number of Subjects With First Hospitalization for Worsening Heart Failure or Death</title>
          <description>The primary efficacy endpoint will evaluate the effect of CRT=ON versus CRT=OFF in time to event of a combined endpoint of all-cause mortality or first hospitalization for worsening heart failure.</description>
          <population>This analysis was carried out according to the intention-to-treat principle. Follow-up was censored at study closure, date of death, LVAD, heart transplant, withdrawal from the study, or loss to follow-up, whichever came first. 4 deaths in CRT OFF group and 1 death in CRT ON group were after LVAD/transplant and are not included in this analysis.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="404"/>
                <count group_id="O2" value="405"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="116"/>
                    <measurement group_id="O2" value="102"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Subjects That Underwent Implant Attempt Without System- or Implant-Related Complications (Complication-Free)</title>
        <description>The primary safety endpoint will evaluate the complication-free rate of the Lumax HF-T CRT-D devices in the narrow QRS subject population.</description>
        <time_frame>6 months</time_frame>
        <population>The primary safety endpoint included all subjects undergoing an implant procedure.</population>
        <group_list>
          <group group_id="O1">
            <title>Subjects That Underwent an Implant Attempt</title>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects That Underwent Implant Attempt Without System- or Implant-Related Complications (Complication-Free)</title>
          <description>The primary safety endpoint will evaluate the complication-free rate of the Lumax HF-T CRT-D devices in the narrow QRS subject population.</description>
          <population>The primary safety endpoint included all subjects undergoing an implant procedure.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="855"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="766"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Rate of Hospitalizations for Worsening Heart Failure (Hospitalizations Per Subject-year)</title>
        <description>Evaluate the effects of CRT=ON compared to CRT=OFF on the rate of hospitalization for worsening heart failure (WHF).</description>
        <time_frame>Study duration from randomization to study exit</time_frame>
        <group_list>
          <group group_id="O1">
            <title>CRT=ON</title>
            <description>Cardiac Resynchronization Therapy activated.</description>
          </group>
          <group group_id="O2">
            <title>CRT=OFF</title>
            <description>Cardiac Resynchronization Therapy deactivated.</description>
          </group>
        </group_list>
        <measure>
          <title>Rate of Hospitalizations for Worsening Heart Failure (Hospitalizations Per Subject-year)</title>
          <description>Evaluate the effects of CRT=ON compared to CRT=OFF on the rate of hospitalization for worsening heart failure (WHF).</description>
          <units>Hospitalizations per subj-yr</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="404"/>
                <count group_id="O2" value="405"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.36"/>
                    <measurement group_id="O2" value="0.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>New York Heart Association (NYHA) Classification Change</title>
        <description>Evaluate the effects of CRT=ON compared to CRT=OFF in relation to the change in NYHA classification.
NYHA classes:
Class I - Subjects with cardiac disease, but without resulting limitation of physical activity. Ordinary physical activity does not cause undue fatigue, palpitation,dyspnea, or anginal pain.
Class II - Subjects with cardiac disease resulting in slight limitation of physical activity. They are comfortable at rest. Ordinary physical activity results in fatigue, palpitation, dyspnea, or anginal pain.
Class III - Subjects with cardiac disease resulting in marked limitation of physical activity. They are comfortable at rest. Less than ordinary activity causes fatigue, palpitation, dyspnea, or anginal pain.
Class IV - Subjects with cardiac disease resulting in inability to carry on any physical activity without discomfort. Symptoms of cardiac insufficiency or of anginal syndrome may be present even at rest. If any physical activity is undertaken, discomfort is increased.</description>
        <time_frame>6 months</time_frame>
        <population>Subjects with Baseline &amp; 6-month NYHA classification. 18 subjects (9 CRT ON, 9 CRT OFF) that were in the study at least 6 months and that did not have 6-month NYHA data, had the most recent post-randomization NYHA inputted using the Last Observation Carried Forward (LOCF) principle.</population>
        <group_list>
          <group group_id="O1">
            <title>CRT=ON</title>
            <description>Cardiac Resynchronization Therapy activated.</description>
          </group>
          <group group_id="O2">
            <title>CRT=OFF</title>
            <description>Cardiac Resynchronization Therapy deactivated.</description>
          </group>
        </group_list>
        <measure>
          <title>New York Heart Association (NYHA) Classification Change</title>
          <description>Evaluate the effects of CRT=ON compared to CRT=OFF in relation to the change in NYHA classification.
NYHA classes:
Class I - Subjects with cardiac disease, but without resulting limitation of physical activity. Ordinary physical activity does not cause undue fatigue, palpitation,dyspnea, or anginal pain.
Class II - Subjects with cardiac disease resulting in slight limitation of physical activity. They are comfortable at rest. Ordinary physical activity results in fatigue, palpitation, dyspnea, or anginal pain.
Class III - Subjects with cardiac disease resulting in marked limitation of physical activity. They are comfortable at rest. Less than ordinary activity causes fatigue, palpitation, dyspnea, or anginal pain.
Class IV - Subjects with cardiac disease resulting in inability to carry on any physical activity without discomfort. Symptoms of cardiac insufficiency or of anginal syndrome may be present even at rest. If any physical activity is undertaken, discomfort is increased.</description>
          <population>Subjects with Baseline &amp; 6-month NYHA classification. 18 subjects (9 CRT ON, 9 CRT OFF) that were in the study at least 6 months and that did not have 6-month NYHA data, had the most recent post-randomization NYHA inputted using the Last Observation Carried Forward (LOCF) principle.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="347"/>
                <count group_id="O2" value="338"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Improved at least 1 Class</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="213"/>
                    <measurement group_id="O2" value="185"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No Change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="116"/>
                    <measurement group_id="O2" value="141"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Deteriorated at least 1 Class</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18"/>
                    <measurement group_id="O2" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Quality of Life (QOL) Scores From Baseline to 6-Month Follow-up</title>
        <description>Quality of Life was evaluated using the Minnesota Living with Heart Failure (MLHF) Quality of Life (QOL) Questionnaire.The questionnaire consists of 21 questions to measure the subjects' perception of how their HF and its treatment affected their ability to live as they wanted during the last month. The questions describe different ways in which some people are affected (i.e. physical, socioeconomic, and psychological impairments). If a question does not apply to a subject or is not related to their HF, then they can answer with a 0. If it does apply to them, then they can rate (from 1 to 5) how much it has affected them. From the 21 questions, the lowest possible total score is 0, and the highest possible total score is 105. A lower score is desirable. Therefore, a negative change in QOL score from baseline to 6 months represents an improvement in quality of life, while a positive change in QOL score from baseline to 6 months represents a worsening in quality of life.</description>
        <time_frame>Changes between baseline and 6 months</time_frame>
        <population>Subjects with Baseline &amp; 6-month QOL scores. 25 subjects (15 CRT ON, 10 CRT OFF) that were in the study at least 6 months and that did not have 6-month QOL data, had 3-month data inputted using the LOCF principle.</population>
        <group_list>
          <group group_id="O1">
            <title>CRT=ON</title>
            <description>Cardiac Resynchronization Therapy activated.</description>
          </group>
          <group group_id="O2">
            <title>CRT=OFF</title>
            <description>Cardiac Resynchronization Therapy deactivated.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Quality of Life (QOL) Scores From Baseline to 6-Month Follow-up</title>
          <description>Quality of Life was evaluated using the Minnesota Living with Heart Failure (MLHF) Quality of Life (QOL) Questionnaire.The questionnaire consists of 21 questions to measure the subjects' perception of how their HF and its treatment affected their ability to live as they wanted during the last month. The questions describe different ways in which some people are affected (i.e. physical, socioeconomic, and psychological impairments). If a question does not apply to a subject or is not related to their HF, then they can answer with a 0. If it does apply to them, then they can rate (from 1 to 5) how much it has affected them. From the 21 questions, the lowest possible total score is 0, and the highest possible total score is 105. A lower score is desirable. Therefore, a negative change in QOL score from baseline to 6 months represents an improvement in quality of life, while a positive change in QOL score from baseline to 6 months represents a worsening in quality of life.</description>
          <population>Subjects with Baseline &amp; 6-month QOL scores. 25 subjects (15 CRT ON, 10 CRT OFF) that were in the study at least 6 months and that did not have 6-month QOL data, had 3-month data inputted using the LOCF principle.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="333"/>
                <count group_id="O2" value="330"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-12.1" spread="21.9"/>
                    <measurement group_id="O2" value="-13.5" spread="21.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Composite Score of Death, Hospitalization for Worsening Heart Failure and Change in Quality of Life (QOL)</title>
        <description>Evaluate the effects of CRT=ON compared to CRT=OFF in relation to a composite endpoint of all-cause mortality, hospitalization for worsening heart failure and change in the MLHF Quality of Life Questionnaire.
This composite endpoint used a weighted scoring scale based on the African-American Heart Failure Trial (A-HeFT) study Endpoint Score. (Taylor, AL, Ziesche, S, Yancy, C, et al. Combination of Isosorbide Dinitrate and Hydralazine in Blacks with Heart Failure. N Engl J Med 2004; 351:2049-57.)
Composite Endpoint Scoring:
Vital Status:
Death (-3),
Survival to end of trial (0),
Hospitalization:
1st hospitalization for HF (-1),
No hospitalization (0),
QOL score:*
Improvement by ≥ 10 units (+2),
Improvement by 5-9 units (+1),
Change by &lt; 5 units (0),
Worsening by 5-9 units (-1),
Worsening by ≥ 10 (-2).
Possible total score -6 to +2.
*QOL score details are provided in Secondary Outcome Measure 5.</description>
        <time_frame>Composite of death, worsening heart failure hospitalization (up to 24 months), and change in QOL (at 6 months)</time_frame>
        <population>Subjects with a potential of 24 months of follow-up.</population>
        <group_list>
          <group group_id="O1">
            <title>CRT=ON</title>
            <description>Cardiac Resynchronization Therapy activated.</description>
          </group>
          <group group_id="O2">
            <title>CRT=OFF</title>
            <description>Cardiac Resynchronization Therapy deactivated.</description>
          </group>
        </group_list>
        <measure>
          <title>Composite Score of Death, Hospitalization for Worsening Heart Failure and Change in Quality of Life (QOL)</title>
          <description>Evaluate the effects of CRT=ON compared to CRT=OFF in relation to a composite endpoint of all-cause mortality, hospitalization for worsening heart failure and change in the MLHF Quality of Life Questionnaire.
This composite endpoint used a weighted scoring scale based on the African-American Heart Failure Trial (A-HeFT) study Endpoint Score. (Taylor, AL, Ziesche, S, Yancy, C, et al. Combination of Isosorbide Dinitrate and Hydralazine in Blacks with Heart Failure. N Engl J Med 2004; 351:2049-57.)
Composite Endpoint Scoring:
Vital Status:
Death (-3),
Survival to end of trial (0),
Hospitalization:
1st hospitalization for HF (-1),
No hospitalization (0),
QOL score:*
Improvement by ≥ 10 units (+2),
Improvement by 5-9 units (+1),
Change by &lt; 5 units (0),
Worsening by 5-9 units (-1),
Worsening by ≥ 10 (-2).
Possible total score -6 to +2.
*QOL score details are provided in Secondary Outcome Measure 5.</description>
          <population>Subjects with a potential of 24 months of follow-up.</population>
          <units>Composite score</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="163"/>
                <count group_id="O2" value="163"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.6" spread="1.9"/>
                    <measurement group_id="O2" value="-1.5" spread="1.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With All-cause Mortality</title>
        <description>Evaluate the all-cause mortality rate between the CRT=ON compared to CRT=OFF group.</description>
        <time_frame>From date of randomization up to date of study exit, with a mean treatment duration of 1.6 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>CRT=ON</title>
            <description>Cardiac Resynchronization Therapy activated.</description>
          </group>
          <group group_id="O2">
            <title>CRT=OFF</title>
            <description>Cardiac Resynchronization Therapy deactivated.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With All-cause Mortality</title>
          <description>Evaluate the all-cause mortality rate between the CRT=ON compared to CRT=OFF group.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="404"/>
                <count group_id="O2" value="405"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45"/>
                    <measurement group_id="O2" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Study duration from date of implant to date of study exit, with a mean implant duration of 1.7 years</time_frame>
      <desc>Subjects could have more than one event. Other adverse event data includes data from non-serious adverse events.</desc>
      <group_list>
        <group group_id="E1">
          <title>CRT=ON</title>
          <description>Cardiac Resynchronization Therapy activated.</description>
        </group>
        <group group_id="E2">
          <title>CRT=OFF</title>
          <description>Cardiac Resynchronization Therapy deactivated.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="45" subjects_at_risk="404"/>
                <counts group_id="E2" subjects_affected="26" subjects_at_risk="405"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="259" subjects_at_risk="404"/>
                <counts group_id="E2" subjects_affected="221" subjects_at_risk="405"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Worsening heart failure</sub_title>
                <counts group_id="E1" events="213" subjects_affected="101" subjects_at_risk="404"/>
                <counts group_id="E2" events="181" subjects_affected="93" subjects_at_risk="405"/>
              </event>
              <event>
                <sub_title>Atrial arrhythmia</sub_title>
                <counts group_id="E1" events="34" subjects_affected="27" subjects_at_risk="404"/>
                <counts group_id="E2" events="35" subjects_affected="25" subjects_at_risk="405"/>
              </event>
              <event>
                <sub_title>Ventricular arrhythmia</sub_title>
                <counts group_id="E1" events="36" subjects_affected="26" subjects_at_risk="404"/>
                <counts group_id="E2" events="29" subjects_affected="22" subjects_at_risk="405"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" events="31" subjects_affected="16" subjects_at_risk="404"/>
                <counts group_id="E2" events="26" subjects_affected="21" subjects_at_risk="405"/>
              </event>
              <event>
                <sub_title>Other cardiovascular</sub_title>
                <counts group_id="E1" events="21" subjects_affected="18" subjects_at_risk="404"/>
                <counts group_id="E2" events="20" subjects_affected="17" subjects_at_risk="405"/>
              </event>
              <event>
                <sub_title>Dyspnea</sub_title>
                <counts group_id="E1" events="16" subjects_affected="16" subjects_at_risk="404"/>
                <counts group_id="E2" events="12" subjects_affected="11" subjects_at_risk="405"/>
              </event>
              <event>
                <sub_title>Coronary artery disease</sub_title>
                <counts group_id="E1" events="13" subjects_affected="13" subjects_at_risk="404"/>
                <counts group_id="E2" events="11" subjects_affected="10" subjects_at_risk="405"/>
              </event>
              <event>
                <sub_title>ICD lead</sub_title>
                <counts group_id="E1" events="26" subjects_affected="23" subjects_at_risk="404"/>
                <counts group_id="E2" events="13" subjects_affected="13" subjects_at_risk="405"/>
              </event>
              <event>
                <sub_title>Lead for right atrial pacing</sub_title>
                <counts group_id="E1" events="21" subjects_affected="18" subjects_at_risk="404"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="405"/>
              </event>
              <event>
                <sub_title>Lead for left ventricular pacing</sub_title>
                <counts group_id="E1" events="21" subjects_affected="18" subjects_at_risk="404"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="405"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="14" subjects_affected="11" subjects_at_risk="404"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="405"/>
              </event>
              <event>
                <sub_title>Angina</sub_title>
                <counts group_id="E1" events="8" subjects_affected="7" subjects_at_risk="404"/>
                <counts group_id="E2" events="13" subjects_affected="12" subjects_at_risk="405"/>
              </event>
              <event>
                <sub_title>Peripheral vascular disease</sub_title>
                <counts group_id="E1" events="8" subjects_affected="6" subjects_at_risk="404"/>
                <counts group_id="E2" events="12" subjects_affected="10" subjects_at_risk="405"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="404"/>
                <counts group_id="E2" events="9" subjects_affected="7" subjects_at_risk="405"/>
              </event>
              <event>
                <sub_title>Cardiac arrest</sub_title>
                <counts group_id="E1" events="13" subjects_affected="11" subjects_at_risk="404"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="405"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="404"/>
                <counts group_id="E2" events="8" subjects_affected="6" subjects_at_risk="405"/>
              </event>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" events="9" subjects_affected="5" subjects_at_risk="404"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="405"/>
              </event>
              <event>
                <sub_title>Stroke</sub_title>
                <counts group_id="E1" events="7" subjects_affected="6" subjects_at_risk="404"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="405"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="404"/>
                <counts group_id="E2" events="7" subjects_affected="5" subjects_at_risk="405"/>
              </event>
              <event>
                <sub_title>Transischemic attack</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="404"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="405"/>
              </event>
              <event>
                <sub_title>Thrombosis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="404"/>
                <counts group_id="E2" events="6" subjects_affected="5" subjects_at_risk="405"/>
              </event>
              <event>
                <sub_title>Fluid accumulation</sub_title>
                <counts group_id="E1" events="7" subjects_affected="5" subjects_at_risk="404"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="405"/>
              </event>
              <event>
                <sub_title>Pulmonary edema</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="404"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="405"/>
              </event>
              <event>
                <sub_title>Cardiac catheterization</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="404"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="405"/>
              </event>
              <event>
                <sub_title>Cardiovascular medication related</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="404"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="405"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="404"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="405"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="404"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="405"/>
              </event>
              <event>
                <sub_title>Valvular heart disease</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="404"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="405"/>
              </event>
              <event>
                <sub_title>Abdominal Aortic Aneurysm</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="404"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="405"/>
              </event>
              <event>
                <sub_title>Edema</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="404"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="405"/>
              </event>
              <event>
                <sub_title>Increased INR</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="404"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="405"/>
              </event>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="404"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="405"/>
              </event>
              <event>
                <sub_title>Bradycardia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="404"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="405"/>
              </event>
              <event>
                <sub_title>Dilated cardiomyopathy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="404"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="405"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="404"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="405"/>
              </event>
              <event>
                <sub_title>Ischemic cardiomyopathy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="404"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="405"/>
              </event>
              <event>
                <sub_title>Weight gain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="404"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="405"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="404"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="405"/>
              </event>
              <event>
                <sub_title>Device related</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="404"/>
                <counts group_id="E2" events="10" subjects_affected="9" subjects_at_risk="405"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Endocrine</sub_title>
                <counts group_id="E1" events="13" subjects_affected="12" subjects_at_risk="404"/>
                <counts group_id="E2" events="6" subjects_affected="4" subjects_at_risk="405"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastrointestinal disorder</sub_title>
                <counts group_id="E1" events="68" subjects_affected="43" subjects_at_risk="404"/>
                <counts group_id="E2" events="41" subjects_affected="28" subjects_at_risk="405"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Other noncardiovascular</sub_title>
                <counts group_id="E1" events="54" subjects_affected="40" subjects_at_risk="404"/>
                <counts group_id="E2" events="55" subjects_affected="36" subjects_at_risk="405"/>
              </event>
              <event>
                <sub_title>Cancer</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="404"/>
                <counts group_id="E2" events="13" subjects_affected="10" subjects_at_risk="405"/>
              </event>
              <event>
                <sub_title>Traumatic injury</sub_title>
                <counts group_id="E1" events="12" subjects_affected="11" subjects_at_risk="404"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="405"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="404"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="405"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Hepatic</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="404"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="405"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" events="77" subjects_affected="58" subjects_at_risk="404"/>
                <counts group_id="E2" events="54" subjects_affected="45" subjects_at_risk="405"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Musculoskeletal disorder</sub_title>
                <counts group_id="E1" events="32" subjects_affected="25" subjects_at_risk="404"/>
                <counts group_id="E2" events="18" subjects_affected="15" subjects_at_risk="405"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Nervous system disorder</sub_title>
                <counts group_id="E1" events="16" subjects_affected="13" subjects_at_risk="404"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="405"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="405"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal disorder</sub_title>
                <counts group_id="E1" events="38" subjects_affected="28" subjects_at_risk="404"/>
                <counts group_id="E2" events="19" subjects_affected="16" subjects_at_risk="405"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Respiratory disorder</sub_title>
                <counts group_id="E1" events="27" subjects_affected="14" subjects_at_risk="404"/>
                <counts group_id="E2" events="38" subjects_affected="22" subjects_at_risk="405"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Implantation related</sub_title>
                <counts group_id="E1" events="19" subjects_affected="17" subjects_at_risk="404"/>
                <counts group_id="E2" events="18" subjects_affected="16" subjects_at_risk="405"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="300" subjects_at_risk="404"/>
                <counts group_id="E2" subjects_affected="274" subjects_at_risk="405"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Worsening heart failure</sub_title>
                <counts group_id="E1" events="32" subjects_affected="29" subjects_at_risk="404"/>
                <counts group_id="E2" events="34" subjects_affected="29" subjects_at_risk="405"/>
              </event>
              <event>
                <sub_title>Atrial arrhythmia</sub_title>
                <counts group_id="E1" events="44" subjects_affected="39" subjects_at_risk="404"/>
                <counts group_id="E2" events="43" subjects_affected="35" subjects_at_risk="405"/>
              </event>
              <event>
                <sub_title>Ventricular arrhythmia</sub_title>
                <counts group_id="E1" events="39" subjects_affected="33" subjects_at_risk="404"/>
                <counts group_id="E2" events="29" subjects_affected="25" subjects_at_risk="405"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" events="21" subjects_affected="20" subjects_at_risk="404"/>
                <counts group_id="E2" events="32" subjects_affected="29" subjects_at_risk="405"/>
              </event>
              <event>
                <sub_title>Dyspnea</sub_title>
                <counts group_id="E1" events="27" subjects_affected="20" subjects_at_risk="404"/>
                <counts group_id="E2" events="32" subjects_affected="30" subjects_at_risk="405"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="28" subjects_affected="27" subjects_at_risk="404"/>
                <counts group_id="E2" events="30" subjects_affected="27" subjects_at_risk="405"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="25" subjects_affected="21" subjects_at_risk="404"/>
                <counts group_id="E2" events="15" subjects_affected="14" subjects_at_risk="405"/>
              </event>
              <event>
                <sub_title>Edema</sub_title>
                <counts group_id="E1" events="23" subjects_affected="21" subjects_at_risk="404"/>
                <counts group_id="E2" events="16" subjects_affected="15" subjects_at_risk="405"/>
              </event>
              <event>
                <sub_title>ICD lead</sub_title>
                <counts group_id="E1" events="34" subjects_affected="28" subjects_at_risk="404"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="405"/>
              </event>
              <event>
                <sub_title>Lead for left ventricular pacing</sub_title>
                <counts group_id="E1" events="55" subjects_affected="49" subjects_at_risk="404"/>
                <counts group_id="E2" events="11" subjects_affected="10" subjects_at_risk="405"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Non-cardiovascular</sub_title>
                <counts group_id="E1" events="602" subjects_affected="203" subjects_at_risk="404"/>
                <counts group_id="E2" events="548" subjects_affected="201" subjects_at_risk="405"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Implant Procedure</sub_title>
                <counts group_id="E1" events="33" subjects_affected="31" subjects_at_risk="404"/>
                <counts group_id="E2" events="46" subjects_affected="41" subjects_at_risk="405"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Endpoint results should be interpreted with caution and take into consideration the early study closure and subsequent reduction in sample size (809 vs. 1258) and events (218 vs. 381). These changes impact the statistical power of the findings.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Kelly Mohr</name_or_title>
      <organization>Biotronik, Inc.</organization>
      <phone>800-547-0394</phone>
      <email>kelly.mohr@biotronik.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

